CELC

Celcuity's stock has been impacted by several events in the past six months. The Phase 3 VIKTORIA-1 trial achieved its primary endpoint, leading to a stock price surge. The FDA accepted Celcuity's NDA for gedatolisib and granted it Priority Review, setting a PDUFA goal date of July 17, 2026. Celcuity released its Q4 and full year 2025 financial results, reporting a narrower-than-expected loss. Analyst firms have maintained or raised their ratings and price targets for CELC. Recent insider selling by two directors has been noted. Celcuity's stock has delivered a significant change of 1,191.23% over the past year.